News | Radiation Therapy | August 16, 2019 Drug Accelerates Blood System’s Recovery After Radiation, Chemotherapy A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem… read more News | Proton Therapy | August 08, 2019 MD Anderson to Expand Proton Therapy Center The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a… read more News | Radiation Therapy | August 15, 2019 First Patient Enrolled in World’s Largest Brain Cancer Clinical Trial Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive… read more News | Brachytherapy Systems | August 14, 2019 Efficacy of Isoray’s Cesium Blu Showcased in Recent Studies August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica read more News | Artificial Intelligence | August 13, 2019 Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that… read more Catalyst PT image courtesy of C-RAD Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communications Image courtesy of Imago Systems News | Neuro Imaging | August 16, 2019 ADHD Medication May Affect Brain Development in Children A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s… read more Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al. News | Mammography | August 14, 2019 Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year… read more Related Content Technology | Interventional Radiology | August 16, 2019 Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to… read more News | Prostate Cancer | December 29, 2015 Prostate Cancer Survival Better With Surgery vs. Radiotherapy December 29, 2015 — A rigorous evaluation of survival rates has shown that cancer patients with localized prostate cancer — the most common form of prostate cancer — have a better chance of survival if treated by surgery than by radiotherapy. These findings hold true even after accounting for type of radiation and the aggressiveness of cancer. This is the most robust analysis (meta-analysis) to date of published literature comparing surgery and radiotherapy for localized prostate cancer. The study is published in the peer-reviewed journal, European Urology.According to senior author, Robert Nam (Odette Cancer Centre, Sunnybrook Research Institute, University of Toronto, Canada):”In the past, studies that have compared the success rates of surgery or radiation have been confusing because of their methods. We have evaluated all the good-quality data comparing surgery and radiotherapy, and the results are pretty conclusive; in general, surgery results in better mortality rates than radiotherapy. Nevertheless, there are times when radiotherapy may be more appropriate than surgery, so it is important that a patient discusses treatment options with his clinician”.Localized prostate cancer — where the cancer is confined to the prostate — accounts for around 80 percent of prostate cancers. Around 400,000 men are diagnosed with prostate cancer each year in Europe, meaning that around 320,000 will suffer from localized prostate cancer. The most common way of treating localized prostate cancers are either with radiotherapy, or with surgery. The choice of radiotherapy or surgery varies according to country. For example, in England and Wales, radiotherapy is used more often than surgery.The researchers conducted a meta-analysis that compared 19 studies including up to 118,830 patients who had undergone treatment with either surgery or radiation.The analysis had to consider a variety of studies that compared different parameters (such as duration of the study). Fifteen of the studies compared patients who died of prostate cancer after surgery or radiation; they found that over the duration of the studies, patients were twice as likely to die from prostate cancer after being treated with radiation, compared to surgery, (Hazard Ratio 2.08, 95 percent confidence interval 1.76-2.47, p < 0.00001).Ten of the studies also looked at overall mortality (where the cause of death was not necessarily from prostate cancer), and found that patients treated with radiation were about one and half times more likely to die sooner than patients who had surgery (HR 1.63, 95 percent confidence interval 1.54-1.73, p < 0.00001)"Both treatment approaches should be discussed with patients prior to the start of therapy," said Nam. "The important thing about this research is that it gives physicians and patients additional, information to consider when making the decision about how to treat localized prostate cancer."This systematic review suggests that survival is better after surgery compared to various forms of radiotherapy,” said Professor Nicolas Mottet (St Étienne, France), chairman of the European Association of Urology Prostate Guideline Panel. “It deserves attention, as it is based on the best available data. However, definitive proof needs a large well-conducted randomized control trial, such as the upcoming PROTECT trial, which is due to report next year. So we certainly need to take this analysis into account, but it doesn't yet give us a definitive answer as to the best treatment. Although this paper should not change clinical practice, I agree with the authors, this analysis gives us important, additional information".References:1. European Urology, www.sciencedirect.com/science/journal/aip/030228382. See http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=29&Gender=1 In North America, there are 220,800 cases of prostate cancer diagnosed each year, meaning that approximately 176,000 are localized http://seer.cancer.gov/statfacts/html/prost.html3. For U.K. statistics, see www.ncin.org.uk/view?rid=1260 FacebookTwitterLinkedInPrint分享 News | Pediatric Imaging | August 14, 2019 Ultrasound Guidance Improves First-attempt Success in IV Access in Children August 14, 2019 – Children’s veins read more News | Patient Positioning Radiation Therapy | August 15, 2019 Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton... read more The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.